AZ, BMS win Xigduo diabetes approval in Europe; Without AbbVie, Abbott Labs profits plummet; Alexion's Soliris wins another orphan designation;

@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma

@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton

@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce

@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce

> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) won EU approval for Xigduo as a treatment for Type 2 diabetes. Release

> Without its pharma division AbbVie ($ABBV), spun off last January, Abbott Laboratories ($ABT) posted a 44% decline in annual profits. Report (sub. req.)

> Alexion Pharmaceuticals ($ALXN) won another orphan drug designation for Soliris, its pricey treatment already approved for two rare diseases. Release | Report

> Still fighting to block Hanmi's rival to its blockbuster stomach drug Nexium, AstraZeneca ($AZN) asked for a full rehearing of their patent fight in U.S. Circuit Court. Report (reg. req.)

> Bayer said its $2.9 billion offer for Norway's Algeta would be open till Feb. 24; the company rolled out a €2 billion ($2.7 billion) bond issue today, in part to finance the potential deal. Report | More

> Germany's Stada said its 2013 sales topped €2 billion ($2.7 billion), according to its preliminary figures. Report

> Pfizer ($PFE) sold its former animal health headquarters in Madison, NJ, to a group of private investors. Report

> The U.K.'s cost-effectiveness watchdogs approved transcranial magnetic stimulation as a treatment for migraine. Report

> Novartis ($NVS) launched a topical diclofenac gel, Voveran TPM, in India. Report

Biotech News

@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech

@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce

@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce

@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce

> Boehringer, Zealand hit reset on GLP-1 diabetes program. More

> U.K. mulls a 'breakthrough' drug program of its own. Article

> Yale researchers chide the FDA for failing to enforce high R&D standards. Coverage

Medical Device News

@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev

@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce

@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce

> Diagnostics buoyed Abbott's Q4 numbers, but diabetes sales declined. Report

> Cohera Medical's surgical sealants attracted a $26.3M Series D. More

> St. Jude Medical reports solid growth, predicts more to come. News

Drug Delivery News

> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News

> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article

> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story

> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece

> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story

> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item

Diagnostics News

> Researchers from Singapore and China find a new esophageal cancer biomarker. More

> A finger-prick blood test could uncover sports concussions on the field. Article

> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story

> FDA approves Affymetrix's blood test for developmental disabilities. Coverage

> Illumina brings next-generation sequencing to Amgen companion Dx deal. News

> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item

And Finally... Yellowstone National Park decided not to vaccinate its roaming bison, the last purebred herd in the U.S., using so-called biobullets. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.